AstraZeneca files Zactima for NSCLC in US and EU
This article was originally published in Scrip
AstraZeneca has filed its oral targeted anticancer Zactima (vandetanib) with both the US FDA and the EMEA, for use in combination with chemotherapy as a second-line treatment for advanced non–small cell lung cancer (NSCLC).
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.